BESREMI
As listed in the register: BESREMI 250 MICROGRAMOS/0,5 ML DE SOLUCION PARA INYECCION EN PLUMA PRECARGADA
250 microgramos/0,5 ml · solución inyectable en pluma precargada
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Ropeginterferón alfa-2b
- Made by
- Aop Orphan Pharmaceuticals Gmbh
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
CanadaNo exact match for this strength and form
Netherlands1 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Aop Orphan Pharmaceuticals Gmbh |
|---|---|
| Active substance | Ropeginterferón alfa-2b |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 250 microgramos/0,5 ml |
| Form | solución inyectable en pluma precargada |
| Classification | L03AB15 · Cancer treatments and immune-system medicines |
| Route | vía subcutánea |
| Marketed | No — authorised but not currently marketed, according to the register |
| Driving | The regulator flags that this medicine can affect the ability to drive. |
| Name in the register | BESREMI 250 MICROGRAMOS/0,5 ML DE SOLUCION PARA INYECCION EN PLUMA PRECARGADA |
| Nº Registro | 1181352001 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.